PSNL - Personalis Inc Company Long-Term Liabilities

Public company logo of Personalis Inc (PSNL)

This chart of the market valuation of Personalis, Inc. (PSNL) debt obligations at 0.03 highlights financial pressure resulting from slow insurance reimbursement and marketing expenses. However, long-term agreements with pharma behemoths for clinical trials support business stability. Personalis, Inc. (PSNL) generates revenue through high-precision genome sequencing, assisting in the selection of personalized therapies and the development of new oncology drugs.

personalis.com (PSNL) Company Long-Term Debt: for the period 07/04/2022 - 10/30/2026

Personalis Corp (PSNL) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price personalis.com|PSNL - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Personalis|PSNL - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Personalis|PSNL - Company Book Value|Market Value to Book Value personalis.com|PSNL - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Personalis, Inc.|PSNL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Personalis Genomics|PSNL - Company Total Debt|Debts to Book Capitalization Personalis|PSNL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Personalis|Immediate Liquidity personalis.com
- earnings and market multiples details:
PSNL - Company Net Income
Fundamental company valuation:PSNL (personalis.com)
Brand item of Personalis, Inc.

To scale genomic oncology monitoring, Personalis, Inc. (PSNL) can leverage long-term corporate liabilities to reduce unit sequencing costs. This indicator aggregates the loan portfolio with maturities exceeding one year, filtering out short-term noise to assess leverage sustainability. Investors must balance the reliability of low debt with the efficiency of borrowed capital within the financing structure of the company's expansion.

Competitors of Personalis, Inc. (PSNL)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Revolution Medicines Inc (RVMD) - Company Long-Term Liabilities|AAPG: Company Long-Term Debts|Long-Term Debt CG Oncology Therapeutics (CGON)|Company Long-Term Debt UroGen Pharma Ltd.|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities ERAS (Erasca)|DCTH (Delcath Systems Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts YMAB (YmAbs)|AURA - Company Long-Term Liabilities|CADL: Company Long-Term Liabilities|ARAY - Company Long-Term Debts|sellaslifesciences.com (SLS) - Company Long-Term Debt|Actuate Therapeutics Inc. - Company Long-Term Loans and Borrowings|CTOR (Citius Oncology, Inc) - Company Long-Term Debts|Long-Term Debt TuHURA HURA|Company Long-Term Debt Protara Therapeutics (TARA)|FATE: Long-Term Liabilities|Company Long-Term Debts WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Long-Term Debt|CSBR - Company Long-Term Debt|Company Long-Term Loans and Borrowings XBIT (XBiotech Inc.)|cel-sci.com (CVM) - Company Long-Term Debt|OSTX - Long-Term Debt Volume|Company Long-Term Debt Radiopharm Theranostics Limited|Long-Term Debt Artiva ARTV|Company Long-Term Debt Adlai Nortye Ltd. (ANL)|Veru Corporation - Company Long-Term Indebtedness|Company Long-Term Debts TPST (Tempest Therapeutics)|Company Long-Term Debts Xilio Therapeutics Inc XLO|RENB - Company Long-Term Debt|MURA: Company Long-Term Debt|KAPA: Company Long-Term Debts|OKUR - Long-Term Debt Volume|Company Long-Term Debt CytoMed Therapeutics Ltd|Curis Corp (CRIS) - Long-Term Debt Volume|Company Long-Term Liabilities APLM (Apollomics, Inc.)|THAR (Tharimmune Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts ADVB (Advanced Biomed)|Long-Term Debt Volume Genprex Inc (GNPX)|CLDI - Company Long-Term Debt|SBFM (Sunshine Biopharma Inc.) - Company Long-Term Indebtedness|XBIO: Company Long-Term Debts|Company Long-Term Liabilities Salarius Pharmaceuticals Inc|Company Long-Term Liabilities PPBT|AON (AONC) - Long-Term Debt Volume|Company Long-Term Debt BeiGene, Ltd. (BGNE)|CKPT: Long-Term Liabilities|Company Long-Term Debt Elevation Oncology, Inc. ELEV|Long-Term Debt Volume iCAD Inc. (ICAD)|IKNA - Company Long-Term Debt|NTBL (Notable Labs Corp) - Company Long-Term Indebtedness|viracta.com (VIRX) - Company Long-Term Debt|MOR (morphosys.com) - Company Long-Term Debt|NAYA (NAYA Biosciences Inc.) - Company Long-Term Debts|Company Long-Term Liabilities Ascentage Pharma Group International (AAPGV)